EQS-News
157 
0 Kommentare
NeuroOne(R) to Report Third Quarter Fiscal Year 2026 Financial Results on Thursday, August 13, 2026, at 8:30 a.m. Eastern Time
- Q3 FY2026 results released Aug 13 2026 8:30 ET
- Investor call and webcast Aug 13 8:30 a.m. ET
- NeuroOne offers high precision electrodes and OneRF
|
EQS-News: NeuroOne Medical Technologies / Key word(s): Financial EDEN PRAIRIE, MINN. - August 3, 2026 (NEWMEDIAWIRE) - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, will release financial results for its fiscal third quarter ended June 30, 2026, before market open on August 13, 2026. |
Management will host an investor conference call and webcast at 8:30 a.m. Eastern time on Thursday, August 13, 2026, to discuss the Company’s fiscal third quarter 2026 financial results, provide a corporate update, and conclude with Q&A from telephone participants. To participate, please use the following information:
Fiscal Third Quarter 2026 Earnings Conference Call
Date: Thursday, August 13, 2026
Time: 8:30 a.m. Eastern time
U.S. Dial-In (Toll Free): 888-506-0062
International Dial-In: 973-528-0011
Participant Access Code: 549778
Webcast:
NMTC FY Q3 2026 Earnings Call Webcast
Please join at least five minutes before the start of the call to ensure timely participation.
A playback of the call will be available through Thursday, August 27, 2026. To listen to the replay, please call 877-481-4010 within the United States or 919-882-2331 when calling internationally, using replay passcode 54304. A webcast replay will also be available using the webcast link above through August 13, 2027.
About NeuroOne
NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.
IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us
View the original release on www.newmediawire.com
News Source: NeuroOne Medical Technologies
03.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News
| Language: | English |
| Company: | NeuroOne Medical Technologies |
| United States | |
| ISIN: | US64130M2098 |
| EQS News ID: | 2376372 |
| End of News | EQS News Service |
|
|
2376372 03.08.2026 CET/CEST
Google bevorzugen.Sie erhalten mehr Inhalte von uns in Ihren Suchergebnissen
URL kopieren
Per E-Mail teilen
Artikel drucken